Clinical Trial Update: Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS) [Phase 2]

View source ↗

Summary

Phase 2 trial update reporting the determination of a safe dose of romiplostim (AMG 531) in patients with myelodysplastic syndromes, with results posted after c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes
• Thrombocytopenia

Drugs mentioned

• Romiplostim (romiplostim)

Snippet

Sponsor: Amgen | Conditions: Thrombocytopenia, MDS | Phase 2 | Status: COMPLETED | Results posted: 2010-11-19